University of Minnesota - Masonic Cancer Center

Minneapolis, MN

Sorting 11 by

Accepting patients

T Cell Receptor Depletion in Stem Cell Transplant

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
Learn more
  • Monoclonal Antibody
  • T Cell (Allogeneic)
  • CD20
  • Phase 2

Accepting patients

OPTIMIZE

A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

A/B TCD Peripheral Blood Stem Cell Transplantation

Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults With Hematological Malignancies
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

PedAL Screening

Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
Learn more
  • Phase 1/2

Accepting patients

Allogeneic Stem Cell Transplant

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

TRX-103

Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)
Learn more
  • T Cell (Allogeneic)
  • Phase 1

Accepting patients

Imetelstat Combination Therapy

A Phase 1 Study of GRN163L (Imetelstat) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia That is in Second or Greater Relapse or That is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy
Learn more
  • Telomerase Inhibitor
  • Phase 1

Accepting patients

GTB-3650 Tri-Specific Killer Engager (TriKE®)

HM2023-05: GTB-3650 (Anti-CD16/IL-15/Anti-CD33) Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML)
Learn more
  • CD16
  • CD33
  • Interleukin 15 (IL-15)
  • Phase 1

Accepting patients

UCB Transplant with Myeloablative Prep

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

Myeloablative Allo Stem Cell Transplant

Myeloablative Allogeneic Hematopoietic Stem Cell Transplant With Related or Unrelated Donor for Hematological Disorders
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 2